The fight against cancer is getting a boost from a growing Checkpoint Inhibitor Refractory Cancer Market. This sector, valued at an estimated USD 38.69 billion in 2023, is projected to experience significant growth due to a rise in patient awareness and expanded uses for existing immunotherapies.
According to a recent analysis, the global Checkpoint Inhibitor Refractory Cancer market is anticipated to grow at a robust Compound Annual Growth Rate (CAGR) of 11.26% between 2023 and 2033. This translates to a staggering market size of approximately USD 112.43 billion by 2033.
Immunotherapy treatment methods are evolving and are one of the most important methods for cancer treatment. Checkpoint inhibitors, such as PD-1/PD-L1, use a focused approach to reduce toxicity, resulting in greater efficacy. The checkpoint inhibitors industry is growing due to the effectiveness of the medicines.
Request Sample Copy of Report
https://www.futuremarketinsights.com/reports/sample/rep-gb-16133
Moreover, the high prevalence of cancer is the major factor that is responsible for the rise in the market revenue of checkpoint inhibitors. Also, technological advancements and innovations will accelerate the market growth over the analysis period.
Other factors include the rise in the cases of a different type of cancers where checkpoint inhibitors are in use, an increase in R&D activity, as well as expected commercial success of upcoming therapies which are going to resolve the issue of primary resistance, and a surge in the usage of approved checkpoint inhibitor therapies in the 7MM are all projected to fuel the revenue share of the market shortly.
Moreover, companies across the world are thoroughly working toward developing new drug therapy options, to treat a wide array of Checkpoint Inhibitor Refractory Cancers. Some of the key players, including BerGenBio, OncoSec Medical, Mirati Therapeutics, CatalYm, and Checkmate Pharmaceuticals, among others, are involved in developing novel therapies for indications such as Melanoma, non-small cell lung cancer (NSCLC), advanced-stage, solid tumors, and others.
In addition, there has been an increase in demand for pembrolizumab (KEYTRUDA) worldwide, attributed to its proven efficiency in treating many FDA-Approved indications such as head and neck squamous cell cancer (HNSCC), non-small cell lung cancer (NSCLC), and melanoma. Hence, the market players are investing more in the development of these products, and this trend is anticipated to continue in the coming years, thus, fostering the market growth.
Further, the factors such as the growing burden of cancer on the global level have been increasing the use of checkpoint inhibitors, as these inhibitors are significant immune and are used as front-line treatments for several types of cancer. Hence, with the increase in the incidence of cancer, the use of checkpoint inhibitors is also increasing. This trend is expected to continue over the analysis period.
Avail Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16133
Key Takeaways from the Market Study
- Global Checkpoint Inhibitor Refractory Cancer Market was valued at US$ 781.0 Billion by 2022-end
- From 2018 to 2022, the market demand expanded at a CAGR of 5.5%
- By Application, the Non-Small Cell Lung segment of the market constitutes the bulk of the market with a market share of 37%
- By End-User, the Hospital Pharmacies segment dominates the market with a share of 48.3%
- From 2023 to 2033, Checkpoint Inhibitor Refractory Cancer sales are expected to flourish at a CAGR of 11.26%.
- By 2033, the market value of Checkpoint Inhibitor Refractory Cancer is expected to reach US$ 112.43 Billion.
A rapid increase in the global prevalence of several cancers globally is one of the major factors that is expected to escalate the growth of the checkpoint inhibitor refractory cancer market in the forthcoming years, remarks an FMI analyst.
Checkpoint Inhibitor Refractory Cancer Market Competitive Landscape
Prominent players in the Checkpoint Inhibitor Refractory Cancer market are Bristol-Myers Squibb, AstraZeneca, Merck, Genentech/Hoffmann-La Roche, Regeneron Pharmaceuticals, Merck KGaA, Pfizer, Bristol-Myers Squibb, Janssen Research and Development, LLC., 4D pharma plc., 4SC AG, OncoSec Medical, Mirati Therapeutics, Ascentage Pharma Group, and ENB Therapeutics, Inc., among others.
Checkpoint Inhibitor Refractory Cancer Market Recent Developments:
- In January 2020, Merck & Co. acquired ArQule Inc., a company that develops therapeutics based on its proprietary Activated Checkpoint Therapy platform.
- In July 2019, Sanofi signed an agreement with Roche for the exclusive over-the-counter (OTC) rights to Tamiflu for the prevention and treatment of influenza or flu in the United States.
Customization Available
https://www.futuremarketinsights.com/customization-available/rep-gb-16133
Key Segments Covered in the Checkpoint Inhibitor Refractory Cancer Industry Analysis
Checkpoint Inhibitor Refractory Cancer Market by Type:
- PD-1 Inhibitors
- PD-L1 Inhibitors
Checkpoint Inhibitor Refractory Cancer Market by Application:
- Hodgkin Lymphoma
- Kidney Cancer
- Melanoma
- Non-Small Cell Lung Cancer
- Others
Checkpoint Inhibitor Refractory Cancer Market by End-User:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
About Healthcare at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization, and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments based on Source, Application, Sales Channel, and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
